Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C20H29NO3 |
| Molecular Weight | 331.4492 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC[C@H](C1)OC(=O)C(O)(C2CCCCC2)C3=CC=CC=C3
InChI
InChIKey=LCFBCKSQWVQIBY-QSVWIEALSA-N
InChI=1S/C20H29NO3/c1-21-14-8-13-18(15-21)24-19(22)20(23,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17-18,23H,3,6-8,11-15H2,1H3/t18-,20?/m1/s1
| Molecular Formula | C20H29NO3 |
| Molecular Weight | 331.4492 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Propenzolate is a pyridine derivative patented by National Research Development Corp. as an anticholinergic agent. Propenzolate is effective antidotes to the cholinesterase-inhibiting action of various organophosphorus compounds. In clinical trials, Propenzolate has an activity that decreases to some extent the secretion of hydrochloric acid and the volume of gastric juice. Adverse effects, including nausea, vomiting, weakness, and drowsiness, as well as xerostomia and cycloplegia, are observed in a high percentage of patients receiving 0.5 to 1.0 mg. every 12 hours.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:42:19 GMT 2023
by
admin
on
Sat Dec 16 16:42:19 GMT 2023
|
| Record UNII |
OP853VBF2G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000083301
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | |||
|
C174806
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | |||
|
SUB09560MIG
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | |||
|
3821
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | |||
|
1334
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | |||
|
DTXSID701017031
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | |||
|
4354-45-4
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | |||
|
OP853VBF2G
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | |||
|
m438
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2111025
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY | |||
|
118984357
Created by
admin on Sat Dec 16 16:42:19 GMT 2023 , Edited by admin on Sat Dec 16 16:42:19 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
